The price of Savara Inc (NASDAQ: SVRA) closed at $5.16 in the last session, up 2.38% from day before closing price of $5.04. On the day, 2143934 shares were traded.
Ratios:
We take a closer look at SVRA’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 15.66 and its Current Ratio is at 15.66. In the meantime, Its Debt-to-Equity ratio is 0.19 whereas as Long-Term Debt/Eq ratio is at 0.19.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, JMP Securities on February 15, 2024, initiated with a Mkt Outperform rating and assigned the stock a target price of $8.
On November 07, 2023, Guggenheim started tracking the stock assigning a Buy rating and target price of $7.
Jefferies Upgraded its Hold to Buy on May 16, 2023, whereas the target price for the stock was revised from $2 to $4.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Dec 28 ’23 when Elam Nevan C sold 93,843 shares for $4.71 per share. The transaction valued at 442,291 led to the insider holds 22,500 shares of the business.
Pauls Matthew sold 84,000 shares of SVRA for $395,900 on Dec 28 ’23. The CHIEF EXECUTIVE OFFICER now owns 1,302,674 shares after completing the transaction at $4.71 per share. On Dec 28 ’23, another insider, Lowrance David L, who serves as the CHIEF FINANCIAL OFFICER of the company, sold 10,000 shares for $4.71 each. As a result, the insider received 47,131 and left with 342,355 shares of the company.
Stock Price History:
Over the past 52 weeks, SVRA has reached a high of $5.70, while it has fallen to a 52-week low of $1.69.
Shares Statistics:
A total of 138.14M shares are outstanding, with a floating share count of 67.84M. Insiders hold about 50.90% of the company’s shares, while institutions hold 42.30% stake in the company.
Earnings Estimates
The company has Zevra Therapeutics, Inc. analysts who recommend its stock at the moment. The consensus estimate for the next quarter is $5.16, with high estimates of $13.60 and low estimates of $12.20.
